Alvocidib - Tolero Pharmaceuticals

Drug Profile

Alvocidib - Tolero Pharmaceuticals

Alternative Names: Alvocidib hydrochloride; Flavopiridol; HL-275; HMR 1275; IND 46211; L 868275; MDL-107826A; NSC 649890

Latest Information Update: 09 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator sanofi-aventis
  • Developer National Cancer Institute (USA); Tolero Pharmaceuticals
  • Class Antineoplastics; Benzopyrans; Flavonoids; Piperidines; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; CDC2 protein kinase inhibitors; Cyclin dependent kinase 9 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Acute myeloid leukaemia; Germ cell and embryonal neoplasms
  • Preclinical Multiple myeloma; Myelodysplastic syndromes
  • No development reported B cell lymphoma; Chronic lymphocytic leukaemia
  • Discontinued HIV infections; Non-small cell lung cancer; Oesophageal cancer; Renal cancer; Reperfusion injury

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Acute-myeloid-leukaemia(Monotherapy) in USA (IV, Infusion)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in B-cell lymphoma(Combination therapy, Second-line therapy or greater) in USA (IV, Infusion)
  • 23 Oct 2017 Preclinical data in Cancer released by Tolero Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top